Agenda

Return

C. 79

To:	Board of Supervisors
From:	William Walker, M.D., Health Services Director
Date:	October 6, 2015

Contra

Costa

County

Subject:

Polymedco Cancer Diagnostics Products LLC. Purchase Order Amendment

APPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR	RECOMMENDATION OF BOARD COMMITTEE

Action of Board On: 10/06/2015

APPROVED AS RECOMMENDED

OTHER

Clerks Notes:

VOTE OF SUPERVISORS

AYE:

John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Mary N. Piepho, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor

Contact:	Anna Roth, 370-5101
cc:	T Scott N Rios Crystal Grayson

I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED: October 6, 2015
David Twa,

BY:	, Deputy

RECOMMENDATION(S):

Approve and Authorize the Purchasing Agent, on behalf of the Health Services Department, to execute an amendment to Purchase Order #53808 with Polymedco Cancer Diagnostic Products, LLC., to add $16,000 for a new total of $115,000 for reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at the Contra Costa Regional Medical Center (CCRMC), with no change in the original term of October 1, 2014 through September 31, 2015.

FISCAL IMPACT:

100% funding is included in the Hospital Enterprise Fund I Budget.

BACKGROUND:

Polymedco’s OC-Auto Micro 80 Analyzer with FOBT-CHECKoc reagents is an automated immunochemical fecal occult blood testing system that detects human red cells only with no interferences from red meat, beets, melons, aspirin, anti-inflammatory drugs and vitamin C. This improvement directs many more of the “right” patients to colonoscopy leading to the earlier detection of polyps and colorectal cancer.

CONSEQUENCE OF NEGATIVE ACTION:

If this Purchase Order is not approved, the CCRMC Clinical Laboratory will not be able to perform additional patient testing for colorectal cancer

CHILDREN'S IMPACT STATEMENT:

Not applicable.